Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro.
The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). Pretreatment with the receptor-inactivating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (1 and 2 x 6 mg/kg) progressively shifted the dose-response curve for NPA to the right, but PRL secretion was still maximally inhibited. Receptor inactivation elicited smaller (2-fold) dextral shifts in the ED50 for the partial agonists (+)- and (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine. These results are consistent with the presence of a sizable receptor reserve at the D2 receptor regulating PRL release in the anterior pituitary. Analogous results were obtained in vitro utilizing primary cultures of anterior pituitary cells. NPA potently inhibited basal PRL release in culture (ED50 0.06 nM, maximal inhibition 83%). Receptor alkylation with phenoxybenzamine (1 microM, 1 hr) did not affect basal PRL release but right-shifted the ED50 for NPA more than 6-fold and attenuated maximal inhibition (to 68%); both effects were significant (P less than .01). The extracellular accumulation of cyclic AMP (cAMP) stimulated by a combination of forskolin (1 microM) and 3-isobutyl-1-methyl xanthine (100 microM) required higher concentrations of NPA (ED50 0.36 nM), and the maximal effect was much smaller (46%). Phenoxybenzamine treatment did not alter either basal or forskolin-stimulated cAMP accumulation, but it reduced the maximal inhibitory response to NPA (to 13%) without shifting the ED50. Plots of receptor occupancy vs. response demonstrated a 60% receptor reserve for NPA inhibition of PRL release, but none for inhibition of cAMP production.(ABSTRACT TRUNCATED AT 250 WORDS)
Meller
E
E
Department of Psychiatry, New York University School of Medicine, New York.
Puza
T
T
Miller
J C
JC
Friedhoff
A J
AJ
Schweitzer
J W
JW
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology; D008297:Male; D010903:Pituitary Gland, Anterior / Q000187:drug effects* / Q000378:metabolism; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D011804:Quinolines / Q000494:pharmacology*; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000378:metabolism; D017448:Receptors, Dopamine D2
D000317:Adrenergic alpha-Antagonists; D015259:Dopamine Agents; D011804:Quinolines; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; C000470:EEDQ; D011388:Prolactin; D000242:Cyclic AMP